- Market Capitalization, $K 709,196
- Shares Outstanding, K 38,211
- Annual Sales, $ 1,130 K
- Annual Income, $ -48,960 K
- 60-Month Beta N/A
- Price/Sales 623.26
- Price/Cash Flow N/A
- Price/Book 2.52
|Period||Period Low||Period High||Performance|
| || |
-0.14 (-0.75%)since 08/23/22
| || |
+2.82 (+17.92%)since 06/23/22
| || |
-14.69 (-44.18%)since 09/23/21
Absci, Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics are part of Zacks top Analyst Blog.
DICE Therapeutics (DICE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.
Topline proof-of-concept data in healthy volunteers and psoriasis patients expected in 2H 2022 SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE...
SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its...
SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its...
CEO Vas Narasimhan is seeking acquisitions under $2 billion.
ShouTi Inc ., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today announced the appointment of Sharon Tetlow to the company’s...
Mary Riley, J.D., appointed as general counselLisa Bowers, MHSA, and Mittie Doyle, M.D., FACR, join board of directors SOUTH SAN FRANCISCO, Calif., March ...
On track to deliver topline proof-of-concept data from Phase 1 clinical trial of oral IL-17 antagonist DC-806 in healthy volunteers and psoriasis patients...
|Dice Therapeutics Inc|
|Bioshares Biotech Clinical Trial|
|FT Multi-Manager Small Cap Opportunities ETF|
|Micro-Cap Ishares ETF|
|Russell 2000 Value Ishares ETF|
|Gx Russell 2000 Covered Call ETF|
|3rd Resistance Point||20.89|
|2nd Resistance Point||19.77|
|1st Resistance Point||19.17|
|1st Support Level||17.45|
|2nd Support Level||16.33|
|3rd Support Level||15.73|